Guangdong Hengrui Pharmaceutical Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-37
RECRUITING15
READOUTS ≤12 MONTHS13
READOUT SLIPPED >6 MO25%
Delay Index: of 12 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Guangdong Hengrui Pharmaceutical Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SHR4597 NCT06940700 |
P2 | Not yet recruiting | Asthma | 60 | 2025-10 |
| SHR-1139 Injection NCT06875934 |
P2 | Active, not recruiting | Moderate to Severe Plaque Psoriasis | 145 | 2025-11 |
| SHR-3045 Injection NCT07233655 |
P2 | Active, not recruiting | Moderate to Severe Active Rheumatoid Arthritis | 30 | 2026-04-21 (-2 mo) |
| SHR-1905 Injection NCT07211542 |
P2 | Recruiting | Moderate-to-severe Atopic Dermatitis | 75 | 2026-09 (+5 mo) |
| HRS-9821 Inhalation Suspension NCT07640451 |
P2 | Recruiting | COPD | 90 | 2026-10 |
| SHR-1819 Injection NCT07688772 |
P3 | Active, not recruiting | Seasonal Allergic Rhinitis | 220 | 2026-12 |
| The SHR-1139 injection NCT07719530 |
P2 | Recruiting | Psoriasis | 60 | 2026-12-31 |
| SHR-2173 injection NCT07354932 |
P2 | Recruiting | Primary IgA Nephropathy | 84 | 2027-04 |
| SHR-1819 Injection NCT07321951 |
P2 | Active, not recruiting | Moderate-to-severe Atopic Dermatitis | 201 | 2027-06 |
| SHR-2173 Injection NCT07229742 |
P2 | Recruiting | Active Lupus Nephritis | 51 | 2027-06 |
| SHR-1139 Injection NCT07444684 |
P2 | Not yet recruiting | Pyoderma Gangrenosum | 20 | 2027-06 |
| SHR-1139 NCT07758075 |
P2 | Not yet recruiting | Plaque Psoriasis | 50 | 2027-07 |
| SHR-1139 intravenous injection. NCT07232576 |
P2 | Active, not recruiting | Adult Patients With Moderately to Severely Active Ulcerative Colitis | 21 | 2027-08 |
| SHR-2173 injection NCT07289763 |
P2 | Recruiting | Primary Membranous Nephropathy | 75 | 2027-08 |
| SHR-2173 injection NCT07622342 |
P2 | Recruiting | Generalized Myasthenia Gravis | 60 | 2027-09 |
| HR-1703 NCT06653322 |
P3 | Active, not recruiting | Asthma With Eosinophilic Phenotype | 401 | 2027-09 |
| SHR-1139 Injection NCT07923851 |
P2 | Not yet recruiting | Palmoplantar Pustulosis of Adults | 40 | 2027-11 |
| SHR-1819 Injection NCT07309055 |
P3 | Recruiting | Adolescents With Moderate-to-severe Atopic Dermatitis | 201 | 2027-11 |
| SHR-1905 Injection NCT07098403 |
P3 | Recruiting | Asthma | 408 | 2028-01 |
| SHR-2173 Injection NCT07299422 |
P2 | Recruiting | Systemic Lupus Erythematosus | 248 | 2028-03 |
| SHR-1905 Injection NCT07132827 |
P3 | Recruiting | Chronic Rhinosinusitis With Nasal Polyps | 280 | 2028-04 |
| HRS-9813 capsules NCT07192939 |
P2 | Recruiting | IPF and PPF | 270 | 2028-06 |
| SHR-1703 Injection NCT06441812 |
P2 | Recruiting | Eosinophilic Asthma Patients | 200 | 2028-09 (+9 mo) |
| SHR-1819 Injection NCT06554509 |
P2/3 | Recruiting | Prurigo Nodularis | 423 | 2028-10 (+27 mo) |
| SHR-1703 NCT05979051 |
P2/3 | Recruiting | Eosinophilic Granulomatosis With Polyangiitis | 166 | 2028-12 (+32 mo) |